Kickback claims lodged against Solvay Pharmaceuticals Inc. by two whistle-blowers were dismissed with prejudice by a federal district court in Texas Dec. 10 after the court ruled that the whistle-blowers failed to uncover sufficient evidence of a nationwide scheme to pay physicians to increase prescriptions of three Solvay drugs (United States ex rel. King v. Solvay S.A., 2015 BL 406241, S.D. Tex., 4:06-cv-02662, 12/10/15).
The U.S. District Court for the Southern District of Texas granted Solvay’s motion for partial summary judgment for all False Claims Act claims against Solvay based on alleged violations of federal and state ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.